DK3150256T3 - Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer - Google Patents
Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer Download PDFInfo
- Publication number
- DK3150256T3 DK3150256T3 DK16185090.4T DK16185090T DK3150256T3 DK 3150256 T3 DK3150256 T3 DK 3150256T3 DK 16185090 T DK16185090 T DK 16185090T DK 3150256 T3 DK3150256 T3 DK 3150256T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- chinese
- combination
- selective inhibitor
- inhibitor
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4595CH2012 | 2012-11-02 | ||
| US201361771812P | 2013-03-02 | 2013-03-02 | |
| EP13792152.4A EP2914343B1 (en) | 2012-11-02 | 2013-11-01 | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3150256T3 true DK3150256T3 (da) | 2020-08-24 |
Family
ID=54264181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16185090.4T DK3150256T3 (da) | 2012-11-02 | 2013-11-01 | Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9694071B2 (enExample) |
| EP (3) | EP3756686A1 (enExample) |
| JP (1) | JP6437441B2 (enExample) |
| KR (2) | KR102185175B1 (enExample) |
| CN (2) | CN110269941A (enExample) |
| AU (3) | AU2013337733B2 (enExample) |
| BR (1) | BR112015009879A8 (enExample) |
| CA (1) | CA2890176C (enExample) |
| CL (1) | CL2015001124A1 (enExample) |
| CY (1) | CY1123938T1 (enExample) |
| DK (1) | DK3150256T3 (enExample) |
| EA (1) | EA030745B1 (enExample) |
| IL (1) | IL238564B (enExample) |
| LT (1) | LT3150256T (enExample) |
| MX (2) | MX375325B (enExample) |
| NZ (1) | NZ708249A (enExample) |
| PL (1) | PL3150256T3 (enExample) |
| RS (1) | RS60844B1 (enExample) |
| SG (2) | SG10201704511RA (enExample) |
| SI (1) | SI3150256T1 (enExample) |
| SM (1) | SMT202000543T1 (enExample) |
| WO (1) | WO2014071125A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| DK2240451T3 (da) | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| PE20180318A1 (es) | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| LT2914296T (lt) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3164506A4 (en) * | 2014-07-01 | 2018-02-28 | Mayo Foundation for Medical Education and Research | Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments |
| MX2018010415A (es) | 2016-03-18 | 2018-11-29 | Hutchinson Fred Cancer Res | Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20). |
| MX2018014577A (es) * | 2016-05-27 | 2019-05-20 | Tg Therapeutics Inc | Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b. |
| UA125216C2 (uk) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
| EP3509634A1 (en) * | 2016-09-09 | 2019-07-17 | TG Therapeutics Inc. | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
| WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| EP3668507A4 (en) * | 2017-08-14 | 2021-05-12 | MEI Pharma, Inc. | Combination therapy |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2021164789A1 (zh) * | 2020-02-21 | 2021-08-26 | 南京明德新药研发有限公司 | 一种吡唑并嘧啶类化合物的晶型及其应用 |
| CN114891005B (zh) * | 2022-03-30 | 2024-01-19 | 武汉九州钰民医药科技有限公司 | 一种乌帕利斯对甲苯磺酸盐的制备工艺 |
| IL317240A (en) * | 2022-06-01 | 2025-01-01 | Tg Therapeutics Inc | Anti-CD20 antibody compositions |
| US11807689B1 (en) * | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| KR20250125901A (ko) * | 2024-02-13 | 2025-08-22 | 연세대학교 산학협력단 | 항-CD20 항체 및 PIKfyve의 억제제를 유효성분으로 포함하는 림프종의 예방 또는 치료용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| JPWO2007102200A1 (ja) | 2006-03-07 | 2009-07-23 | 国立大学法人大阪大学 | 抗ｃｄ２０モノクローナル抗体 |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
| US20110280913A1 (en) * | 2008-07-31 | 2011-11-17 | The Ohio State University | Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders |
| FR2939314A1 (fr) * | 2008-12-04 | 2010-06-11 | Univ Victor Segalen Bordeaux 2 | Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales |
| AU2010224125B2 (en) * | 2009-03-12 | 2015-05-14 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| AP2012006294A0 (en) | 2009-11-05 | 2012-06-30 | Rhizen Pharmaceuticals Sa | Novel kinase modulators. |
| MX357043B (es) * | 2012-07-04 | 2018-06-25 | Rhizen Pharmaceuticals Sa | Inhibidores selectivos de pi3k delta. |
-
2013
- 2013-11-01 EP EP20175073.4A patent/EP3756686A1/en not_active Withdrawn
- 2013-11-01 LT LTEP16185090.4T patent/LT3150256T/lt unknown
- 2013-11-01 AU AU2013337733A patent/AU2013337733B2/en not_active Ceased
- 2013-11-01 SI SI201331772T patent/SI3150256T1/sl unknown
- 2013-11-01 CN CN201910562572.1A patent/CN110269941A/zh active Pending
- 2013-11-01 KR KR1020157014678A patent/KR102185175B1/ko not_active Expired - Fee Related
- 2013-11-01 KR KR1020207033964A patent/KR102341275B1/ko not_active Expired - Fee Related
- 2013-11-01 MX MX2015005555A patent/MX375325B/es active IP Right Grant
- 2013-11-01 WO PCT/US2013/067956 patent/WO2014071125A1/en not_active Ceased
- 2013-11-01 SM SM20200543T patent/SMT202000543T1/it unknown
- 2013-11-01 RS RS20201003A patent/RS60844B1/sr unknown
- 2013-11-01 BR BR112015009879A patent/BR112015009879A8/pt not_active Application Discontinuation
- 2013-11-01 JP JP2015540798A patent/JP6437441B2/ja not_active Expired - Fee Related
- 2013-11-01 SG SG10201704511RA patent/SG10201704511RA/en unknown
- 2013-11-01 EP EP16185090.4A patent/EP3150256B1/en active Active
- 2013-11-01 US US14/440,139 patent/US9694071B2/en not_active Expired - Fee Related
- 2013-11-01 CA CA2890176A patent/CA2890176C/en not_active Expired - Fee Related
- 2013-11-01 NZ NZ708249A patent/NZ708249A/en not_active IP Right Cessation
- 2013-11-01 DK DK16185090.4T patent/DK3150256T3/da active
- 2013-11-01 EP EP13792152.4A patent/EP2914343B1/en not_active Not-in-force
- 2013-11-01 PL PL16185090T patent/PL3150256T3/pl unknown
- 2013-11-01 EA EA201590866A patent/EA030745B1/ru unknown
- 2013-11-01 CN CN201380069143.1A patent/CN105073197B/zh not_active Expired - Fee Related
- 2013-11-01 SG SG11201503393SA patent/SG11201503393SA/en unknown
-
2015
- 2015-04-29 CL CL2015001124A patent/CL2015001124A1/es unknown
- 2015-04-30 MX MX2020009919A patent/MX2020009919A/es unknown
- 2015-04-30 IL IL238564A patent/IL238564B/en active IP Right Grant
-
2017
- 2017-06-28 US US15/635,733 patent/US10729768B2/en not_active Expired - Fee Related
-
2018
- 2018-05-22 AU AU2018203579A patent/AU2018203579B2/en not_active Ceased
-
2020
- 2020-05-25 AU AU2020203417A patent/AU2020203417A1/en not_active Abandoned
- 2020-06-29 US US16/946,585 patent/US20200323981A1/en not_active Abandoned
- 2020-09-09 CY CY20201100851T patent/CY1123938T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3150256T3 (da) | Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer | |
| IL267681B (en) | Selective grp94 inhibitors and uses thereof | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
| DK3290407T3 (da) | Bromodomæneinhibitorer | |
| CO7071096A2 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| EP2723766A4 (en) | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR | |
| EP2723367A4 (en) | Glucagon/glp-1 receptor co-agonists | |
| DK3683235T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| DK3026062T3 (da) | Anti-pd-1-antistof og anvendelse deraf | |
| BR112015002193A2 (pt) | anticorpos anti-etbr e imunoconjugados | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| EP2948519A4 (en) | DELAYED GELER | |
| DK3540429T3 (da) | Indretning og fremgangsmåder til anvendelse af indretning til detektion af hyperammoniæmi | |
| HRP20181457T1 (hr) | Anti-htra1 protutijela i postupci uporabe | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| DK3063144T3 (da) | Antiparasitære og pesticid-isoxazolinforbindelser | |
| DK3068776T3 (da) | Inhibitorer af replikation af influenzavira | |
| DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
| DK2981541T3 (da) | Syntese og anvendelse af isotopmærkede glycaner | |
| DK3029038T3 (da) | Tetrazolinonforbindelse og anvendelse deraf | |
| EP3045047A4 (en) | EMULSIFIED COMPOSITION AND MILK DRINK | |
| PL3042669T3 (pl) | Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy |